2017 top 100 pharmaceutical brand enterprises of the Chinese nation publicized various key products to attract attention

[industry trends of China Pharmaceutical network] on September 8, the "2017 list of top 100 Chinese pharmaceutical brand enterprises and 2018 China traditional Chinese medicine industry development forum" was held in Bozhou, Anhui Province This conference is sponsored by the chamber of Commerce of the medical and pharmaceutical industry of the all China Federation of industry and commerce It aims to promote national medicine, build national brands, set a benchmark, play an exemplary role and promote the development of the traditional Chinese medicine industry It is reported that in the "2017 list of top 100 brand enterprises of Chinese medicine" released at the conference, Yangzijiang pharmaceutical, revisionary pharmaceutical, Yunnan Baiyao, Changbu pharmaceutical and Kangmei pharmaceutical occupy the top five In addition, the top 100 enterprises' top products also attracted strong attention in this meeting Yangzijiang pharmaceutical's key products: Lanqin oral liquid, from the first-line workers in the Yangzijiang Pharmaceutical Workshop, to the staff in the laboratory, to the deputy director of the quality control department, often heard the words "drug quality" Yangzijiang pharmaceutical has penetrated the concept of quality as the core into every employee's heart The author understands that in 2010, the Lanqin oral liquid produced by Yangzijiang pharmaceutical industry was designated by the former Ministry of health as the traditional Chinese medicine for the treatment of common cases of HFMD in the guidelines for the diagnosis and treatment of HFMD (2010 version) "Taking Lanqin oral liquid as an example, our internal control release standard is superior to the relevant national standards in terms of density value, pH value, microbial limit and loading difference," according to the relevant persons of the enterprise And according to the requirements of the new GMP, carry out product stability inspection, quality annual review and other work, continuous improvement, to ensure the stable production of qualified products Key products of revisionmedicine industry: Yiqi Yangxue oral liquid revisionmedicine Group Co., Ltd is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing, drug chain operation and standard cultivation of traditional Chinese medicine of proprietary medicine, chemical medicine and biological medicine At the same time, we should focus on the main pharmaceutical industry and march into the big health industry, tourism industry and pension industry It is reported that at present, the revised pharmaceutical industry can produce more than 1000 kinds of drugs and nearly 1000 kinds of health food and cosmetics in 23 dosage forms, such as "starshu", "Xiaomi suppository", "Yiqi Yangxue oral liquid" The group has enterprise technology center, engineering center and postdoctoral workstation Yunnan Baiyao fist products: Yunnan Baiyao series products have attracted much attention since the start of mixed ownership reform Recently, Yunnan Baiyao replied that after the "mixed reform", Yunnan Baiyao was never a private enterprise; its revenue reached a record high At present, the main products driving the performance are Yunnan Baiyao oral care series products, including traditional Yunnan Baiyao toothpaste, jinkoujian toothpaste, Yiyou Qingxin toothpaste, Yunkang toothpaste and Yunnan Baiyao children's toothpaste Step pharmaceutical products: from January to June 2018, Naoxintong capsule achieved a total operating revenue of 5.748 billion yuan, a decrease of 0.06% over the same period of last year, and a net profit of 701 million yuan belonging to the shareholders of the parent company, a year-on-year increase of 3.37% Step pharmaceutical has a strong competitiveness in the field of cardiovascular and cerebrovascular drugs At present, seven varieties of Naoxintong capsule, Wenxin Granules, Danhong injection, Guhong injection, compound naopeptidyl glycoside injection, compound Qu peptide injection and ginkgo honey ring oral solution have been developed Key products of Kangmei pharmaceutical industry: in the first half of 2018, the performance of Kangmei pharmaceutical industry maintained a steady growth, achieving an operating revenue of 16.959 billion yuan, a year-on-year increase of 27.88%; a net profit of 2.605 billion yuan, a year-on-year increase of 21.06%; and a net profit of 2.582 billion yuan, a year-on-year increase of 20.32% At present, Kangmei pharmaceutical is one of the traditional Chinese medicine enterprises with relatively complete business chain, rich medical and health resources and strong integration ability Its traditional Chinese medicine sector is the business sector with relatively high business income of Kangmei pharmaceutical, while its herbal pieces business is in the leading position in the industry, and its production and marketing scale ranks first Attached is the complete list (1) (2) (3) (4) (5) (6) (picture source: Pharmaceutical Club)